Company Filing History:
Years Active: 2017-2021
Title: David Conrad: Innovator in Immunogenic Formulations
Introduction
David Conrad is a notable inventor based in Ottawa, Canada. He has made significant contributions to the field of immunology through his innovative patents. With a total of two patents to his name, Conrad is recognized for his work in developing novel therapeutic approaches.
Latest Patents
Conrad's latest patents include "Non-replicating virus-derived particles and uses thereof." This patent describes a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while exhibiting tropism against immortalized cells. The particle may also possess cytolytic properties against these cells. Another significant patent is "Virally infected hematopoietic cells and uses thereof." This patent outlines an immunogenic formulation that includes virus-modulated hematopoietic cancer cells, which are generated from viable hematopoietic cancer cells obtained from the patient. The formulation aims to enhance the immunogenicity of these cancer cells through ex vivo infection with a virus.
Career Highlights
David Conrad is currently associated with Celverum Inc., where he continues to advance his research and development efforts. His work focuses on innovative solutions that leverage the immune system to combat cancer.
Collaborations
Conrad collaborates with notable colleagues, including John Cameron Bell and Cory Batenchuk, who contribute to his research endeavors.
Conclusion
David Conrad's contributions to immunology through his patents reflect his commitment to advancing medical science. His innovative approaches have the potential to significantly impact cancer treatment and immunotherapy.